Biocon (BIOCON) Aperçu de l'action
Biocon Limited, avec ses filiales, fabrique et vend des produits biotechnologiques et des services de recherche en Inde, au Brésil, à Singapour et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 4/6 |
| Performances passées | 4/6 |
| Santé financière | 4/6 |
| Dividendes | 1/6 |
BIOCON Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biocon Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹390.65 |
| Plus haut sur 52 semaines | ₹447.15 |
| Plus bas sur 52 semaines | ₹337.05 |
| Bêta | 0.30 |
| Variation sur 1 mois | -8.60% |
| Variation sur 3 mois | -6.77% |
| Variation sur 1 an | 6.97% |
| Variation sur 3 ans | 41.16% |
| Variation sur 5 ans | 3.51% |
| Évolution depuis l'introduction en bourse | 868.45% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Sep 04
BIOCON: Slower Margin Recovery Will Restrict Future P/E Upside
Analysts have raised their fair value estimate for Biocon from ₹298.76 to ₹326.00, citing updated assumptions on revenue growth, margins, and future P/E that they believe better reflect the company’s long-term earnings potential. Analyst Commentary on Biocon While the higher fair value estimate signals more confidence in Biocon’s earnings power, not all commentary skews positive.
Mise à jour du récit • Aug 21
BIOCON: Margin Execution And Cost Discipline Will Underpin Higher Fair Value
Analysts have lifted their fair value estimate for Biocon to ₹534 from ₹506, citing slightly higher required returns, more moderate revenue growth assumptions, stronger profit margin expectations, and a lower future P/E multiple in their refreshed price target work. Analyst Commentary Bullish analysts looking at Biocon are framing the refreshed fair value as part of a broader move toward more disciplined expectations on returns, growth, and profitability.Article d’analyse • Aug 08
Earnings Miss: Biocon Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Biocon Limited ( NSE:BIOCON ), which a week ago released some disappointing...
Mise à jour du récit • Aug 07
BIOCON: Execution On Margin Plans And Biosimilars Pipeline Will Support Measured Upside
Analysts have raised the Biocon fair value estimate from ₹416.53 to ₹429.67, citing updated assumptions that include a revised discount rate, slightly adjusted expectations for revenue growth and profit margins, and a higher future P/E multiple in line with recent sector research. Analyst Commentary Recent Street research around peers in the life sciences and diagnostics space provides useful context for how analysts are thinking about companies like Biocon, particularly on valuation, execution and long term growth visibility.Recent updates
Mise à jour du récit • Sep 04
BIOCON: Slower Margin Recovery Will Restrict Future P/E Upside
Analysts have raised their fair value estimate for Biocon from ₹298.76 to ₹326.00, citing updated assumptions on revenue growth, margins, and future P/E that they believe better reflect the company’s long-term earnings potential. Analyst Commentary on Biocon While the higher fair value estimate signals more confidence in Biocon’s earnings power, not all commentary skews positive.Mise à jour du récit • Aug 21
BIOCON: Margin Execution And Cost Discipline Will Underpin Higher Fair Value
Analysts have lifted their fair value estimate for Biocon to ₹534 from ₹506, citing slightly higher required returns, more moderate revenue growth assumptions, stronger profit margin expectations, and a lower future P/E multiple in their refreshed price target work. Analyst Commentary Bullish analysts looking at Biocon are framing the refreshed fair value as part of a broader move toward more disciplined expectations on returns, growth, and profitability.Article d’analyse • Aug 08
Earnings Miss: Biocon Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Biocon Limited ( NSE:BIOCON ), which a week ago released some disappointing...Mise à jour du récit • Aug 07
BIOCON: Execution On Margin Plans And Biosimilars Pipeline Will Support Measured Upside
Analysts have raised the Biocon fair value estimate from ₹416.53 to ₹429.67, citing updated assumptions that include a revised discount rate, slightly adjusted expectations for revenue growth and profit margins, and a higher future P/E multiple in line with recent sector research. Analyst Commentary Recent Street research around peers in the life sciences and diagnostics space provides useful context for how analysts are thinking about companies like Biocon, particularly on valuation, execution and long term growth visibility.Mise à jour du récit • Jun 15
BIOCON: Future Margin Reset Will Support Biosimilars Expansion And Leadership Transition
Narrative Update Analysts have trimmed Biocon's fair value estimate to ₹506.0 from ₹544.20 as they reset expectations around profit margin assumptions and a higher future P/E, while also fine tuning discount rate and revenue growth inputs. Analyst Commentary Recent Street commentary around related life sciences companies highlights how bullish analysts think about valuation resets, margin potential and recovery timelines.Mise à jour du récit • Jun 01
BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside
Analysts have nudged their fair value estimate for Biocon slightly higher to about ₹299 from roughly ₹296, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. The rationale is informed by recent Street research on peer companies that highlights the impact of tougher macro conditions, underappreciated balance sheet items and potential margin improvements under refreshed management teams.Article d’analyse • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...Mise à jour du récit • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.Mise à jour du récit • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Mise à jour du récit • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.Mise à jour du récit • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Mise à jour du récit • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Mise à jour du récit • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Mise à jour du récit • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Mise à jour du récit • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Mise à jour du récit • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Mise à jour du récit • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Article d’analyse • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Mise à jour du récit • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Article d’analyse • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Mise à jour du récit • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Article d’analyse • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Mise à jour du récit • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Mise à jour du récit • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Article d’analyse • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
Nouveau récit • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Rendement pour les actionnaires
| BIOCON | IN Biotechs | IN Marché | |
|---|---|---|---|
| 7D | -1.7% | -1.6% | -1.4% |
| 1Y | 7.0% | 6.0% | -1.2% |
Rendement vs Industrie: BIOCON correspondait au secteur Indian Biotechs qui a rapporté 6 % au cours de l'année écoulée.
Rendement vs marché: BIOCON a dépassé le marché Indian qui a rapporté -1.2 % au cours de l'année écoulée.
Volatilité des prix
| BIOCON volatility | |
|---|---|
| BIOCON Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Cours de l'action stable: BIOCON n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de BIOCON ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1978 | 16,447 | Shreehas Tambe | www.biocon.com |
Biocon Limited, avec ses filiales, fabrique et vend des produits biotechnologiques et des services de recherche en Inde, au Brésil, à Singapour et dans le monde entier. Elle opère à travers quatre segments : les produits génériques, les nouveaux produits biologiques, les biosimilaires et les services de recherche. La société propose des formulations génériques et des produits API, notamment des antidiabétiques, des immunosuppresseurs, des médicaments contre la sclérose en plaques, des anticancéreux/oncologiques et d'autres produits ; de nouveaux produits biologiques, tels que la molécule contre le cancer de la tête et du cou ; de nouveaux produits en cours de développement comprenant des molécules contre le psoriasis ; et des produits biosimilaires composés d'insulines, de trastuzumab, de pegfilgrastim et de bevacizumab.
Biocon Limited Résumé des fondamentaux
| BIOCON statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹632.66b |
| Bénéfices(TTM) | ₹4.95b |
| Recettes(TTM) | ₹173.21b |
127.7x
Ratio P/E3.7x
Ratio P/SLe site BIOCON est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BIOCON compte de résultat (TTM) | |
|---|---|
| Recettes | ₹173.21b |
| Coût des recettes | ₹67.23b |
| Marge brute | ₹105.98b |
| Autres dépenses | ₹101.03b |
| Les revenus | ₹4.95b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 3.06 |
| Marge brute | 61.19% |
| Marge bénéficiaire nette | 2.86% |
| Ratio dettes/capitaux propres | 42.1% |
Quelles ont été les performances à long terme de BIOCON?
Voir les performances historiques et les comparaisonsDividendes
0.1%
Rendement actuel des dividendes18%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/11 04:10 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Biocon Limited est couverte par 41 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |